Literature DB >> 27272779

Activation of the PERK-eIF2α Pathway Is Associated with Tumor-infiltrating Lymphocytes in HER2-Positive Breast Cancer.

Joo Young Kim1, Sun-Hee Heo2, In Hye Song2, In Ah Park2, Young-Ae Kim2, Gyungyub Gong2, Hee Jin Lee3.   

Abstract

BACKGROUND: We evaluated endoplasmic reticulum stress and unfolded protein response (UPR) activation, as possible mechanisms for influx of tumor infiltrating lymphocytes (TILs), and the correlation between UPR activation and mammalian target of rapamycin (mTOR) pathway activation.
MATERIALS AND METHODS: TILs and the immunohistochemical expression of protein kinase RNA-like endoplasmic reticulum kinase (PERK), phospho-eukaryotic translation initiation factor 2α (p-eIF2α) and phosphorylated S6 (pS6) were evaluated in 447 human epidermal growth factor receptor 2 (HER2)-positive breast cancer tissues.
RESULTS: High expression of PERK, p-eIF2α and pS6 was observed in 270 (60.4%), 259 (57.9%), and 187 (41.8%) cases, respectively, and was significantly associated with a high histological grade, high numbers of TILs, peritumoral lymphocytic infiltration, and tertiary lymphoid structures in HER2-positive breast cancer tissues.
CONCLUSION: The results suggest endoplasmic reticulum stress and UPR activation as possible mechanisms for the influx of TILs in HER2-positive breast cancer. Evaluation of PERK and p-eIF2α expression might be important in identifying targets for cancer therapies in modulating endoplasmic reticulum stress. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Breast cancer; HER2; PERK; p-eIF2α; pS6; tumor-infiltrating lymphocytes

Mesh:

Substances:

Year:  2016        PMID: 27272779

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

Review 1.  Role of the unfolded protein response in determining the fate of tumor cells and the promise of multi-targeted therapies.

Authors:  Kunyu Shen; David W Johnson; David A Vesey; Michael A McGuckin; Glenda C Gobe
Journal:  Cell Stress Chaperones       Date:  2017-09-27       Impact factor: 3.667

2.  mTOR Pathway Activation Assessed by Immunohistochemistry in Cervical Biopsies of HPV-associated Endocervical Adenocarcinomas (HPVA): Correlation With Silva Invasion Patterns.

Authors:  Sheila Segura; Simona Stolnicu; Monica Boros; Kay Park; Pedro Ramirez; Gloria Salvo; Denise Frosina; Achim Jungbluth; Robert A Soslow
Journal:  Appl Immunohistochem Mol Morphol       Date:  2021-08-01

3.  Association of increased primary breast tumor AGR2 with decreased disease-specific survival.

Authors:  Phoebe Ann; Brandon-Luke L Seagle; Arunima Shilpi; Manoj Kandpal; Shohreh Shahabi
Journal:  Oncotarget       Date:  2018-05-01

4.  Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.

Authors:  Miseon Lee; In Ah Park; Sun-Hee Heo; Young-Ae Kim; Gyungyub Gong; Hee Jin Lee
Journal:  J Pathol Transl Med       Date:  2019-03-11

5.  An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy.

Authors:  Cedric Darini; Nour Ghaddar; Catherine Chabot; Gloria Assaker; Siham Sabri; Shuo Wang; Jothilatha Krishnamoorthy; Marguerite Buchanan; Adriana Aguilar-Mahecha; Bassam Abdulkarim; Jean Deschenes; Jose Torres; Josie Ursini-Siegel; Mark Basik; Antonis E Koromilas
Journal:  Nat Commun       Date:  2019-05-13       Impact factor: 14.919

6.  Non-steroidal anti-inflammatory drugs induce immunogenic cell death in suppressing colorectal tumorigenesis.

Authors:  Rochelle Fletcher; Jingshan Tong; Denise Risnik; Brian J Leibowitz; Yi-Jun Wang; Fernando Concha-Benavente; Jonathan M DeLiberty; Donna B Stolz; Reet K Pai; Robert L Ferris; Robert E Schoen; Jian Yu; Lin Zhang
Journal:  Oncogene       Date:  2021-02-18       Impact factor: 9.867

7.  Expression of Immunoproteasome Subunit LMP7 in Breast Cancer and Its Association with Immune-Related Markers.

Authors:  Miseon Lee; In Hye Song; Sun-Hee Heo; Young-Ae Kim; In Ah Park; Won Seon Bang; Hye Seon Park; Gyungyub Gong; Hee Jin Lee
Journal:  Cancer Res Treat       Date:  2018-02-26       Impact factor: 4.679

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.